CSBIO(SZ:300255) Xin Lang Cai Jing·2025-10-21 01:31Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changshan Pharmaceutical, including stock price movements and trading volumes [1][2] - On October 20, Changshan Pharmaceutical's stock rose by 4.60%, with a trading volume of 1.415 billion yuan, and a net financing purchase of 37.36 million yuan [1] - As of October 20, the total margin balance for Changshan Pharmaceutical reached 2.088 billion yuan, accounting for 4.46% of its market capitalization, indicating a high level of financing activity [1] Group 2 - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04%, while the average circulating shares per person increased by 2.08% to 20,094 shares [2] - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.09 million yuan, reflecting a year-on-year increase of 37.98% in losses [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the past three years [3]